Lawyers and Settlements
Home Page >> Lawsuits Filed >> Lawsuit: Human Genome Sciences Inc

Human Genome Sciences Inc HGSI Securities Stock Fraud

Company: Human Genome Sciences Inc
Ticker Symbol: HGSI
Class Period: Jul-20-09 to Nov-11-10
Date Filed: Mar-23-12
Lead Plaintiff Deadline: May-22-12
Court: District of Maryland
San Diego, CA: A securities lawsuit is pending in the U.S. District Court for the District of Maryland against Human Genome Sciences Inc. ("HGSI" or the "Company") and certain of its officers and directors on behalf of all purchasers of the common stock of Human Genome Sciences Inc., between July 20, 2009 and November 11, 2010, inclusive (the "Class Period").

The lawsuit alleges that the defendants made false or misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Claims that the Company and certain of its officers and directors also violated the Securities Act of 1933 in connection with registered public stock offerings that were conducted on July 28, 2009 at $14 per share and on December 2, 2009 at $15.50 per share, through underwriters Citi, Goldman Sachs & Co., J.P.Morgan, Morgan Stanley, UBS Investment Bank and Credit Suisse are also being investigated.

HGSI designs and markets biopharmaceutical products. The complaint alleges that during the Class Period, defendants made materially false and misleading statements concerning a potential new drug, Benlysta, also called belimumab, for the treatment of Systemic Lupus Erythematosus, which is a chronic, life-threatening autoimmune disease.

Specifically, the complaint alleges that defendants failed to disclose that in clinical drug trials they conducted, Benlysta was associated with suicide, and that when this was first disclosed by the U.S. Food and Drug Administration on November 12, 2010, the price of HGSI's common stock dropped precipitously, causing investor losses. The complaint also alleges that meanwhile, HGSI had sold 44.5 million shares of its common stock to the public, receiving approximately $850 million in net proceeds.

If you acquired the securities of the defendants during the Class Period you may, no later than the Lead Plaintiff Deadline shown above, request that the Court appoint you as lead plaintiff through counsel of your choice. You may also choose to remain an absent class member. A lead plaintiff must meet certain requirements.

Human Genome Sciences Inc HGSI Securities Fraud Legal Help

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible Human Genome Sciences Inc securities class action lawsuit. Please click the link below to submit your complaint for a free evaluation.
Published on Mar-23-12


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.

*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Securities Legal Help

First name:

Last name:

Email address:

Phone number(s):

Zip/Postal Code:

Describe your complaint:

By submitting this form I agree to the Terms of Service.
There is no cost to submit this form.
I would like to be interviewed by a journalist.
Receive our weekly newsletter with the latest lawsuit news and legal information.

Check Claim Status Advertise with us Legal Funding

Related Lawsuits

Legal Services:

FAQ | TOS | Privacy | Disclaimer | About Us | Contact Us | Press | Advertise | Member Login | Site Map | View Mobile Website

American Bar Association - Proud Member   Better Business Bureau   CAALA   Best of the Web Approved   Public Justice

This work is licensed under a Creative Commons Attribution-NoDerivs 3.0 Unported License © 2001-2017 Online Legal Media. All rights reserved.

Visit other Online Legal Media Websites: